PMID- 19254704 OWN - NLM STAT- MEDLINE DCOM- 20090706 LR - 20171116 IS - 1873-3492 (Electronic) IS - 0009-8981 (Linking) VI - 403 IP - 1-2 DP - 2009 May TI - Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. PG - 173-7 LID - 10.1016/j.cca.2009.02.013 [doi] AB - BACKGROUND: Metabolic syndrome (MetS) predisposes to cardiovascular complications. Increased concentrations of pro-inflammatory mediators and imbalanced concentrations of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) may reflect the pathophysiology of MetS. We compared the circulating levels of MMPs, TIMPs, and inflammatory mediators in MetS patients with those found in healthy controls. METHODS: We studied 25 healthy subjects and 25 MetS patients. The plasma levels of pro-MMP-2 and pro-MMP-9 were determined by gelatin zymography. The plasma concentrations of MMP-8, MMP-3, TIMP-1, TIMP-2, monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), intercellular adhesion molecule (sICAM-1), and sP-selectin were measured by ELISA kits. RESULTS: We found higher sP-selectin, sICAM-1, MCP-1, and IL-6 (all P<0.05) concentrations in MetS patients compared with healthy controls. No differences in pro-MMP-2, MMP-3, and TIMP-2 levels were found (all P>0.05). However, we found higher pro-MMP-9, MMP-8, and TIMP-1 levels in MetS patients compared with healthy controls (all P<0.05). CONCLUSIONS: Patients with MetS have increased circulating concentrations of pro-MMP-9, MMP-8, and TIMP-1 that are associated with increased concentrations of pro-inflammatory mediators and adhesion molecules. These findings suggest that MMPs may have a role in the increased cardiovascular risk of MetS patients. Pharmacological interventions targeting MMPs, especially MMP-9 and MMP-8 deserve further investigation in MetS patients. FAU - Goncalves, Flavia M AU - Goncalves FM AD - Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, 13081-970, Campinas, SP, Brazil. FAU - Jacob-Ferreira, Anna L B AU - Jacob-Ferreira AL FAU - Gomes, Valeria A AU - Gomes VA FAU - Casella-Filho, Antonio AU - Casella-Filho A FAU - Chagas, Antonio C P AU - Chagas AC FAU - Marcaccini, Andrea M AU - Marcaccini AM FAU - Gerlach, Raquel F AU - Gerlach RF FAU - Tanus-Santos, Jose E AU - Tanus-Santos JE LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090228 PL - Netherlands TA - Clin Chim Acta JT - Clinica chimica acta; international journal of clinical chemistry JID - 1302422 RN - 0 (Biomarkers) RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) RN - 0 (Interleukin-6) RN - 0 (Selectins) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.24.34 (Matrix Metalloproteinase 8) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Biomarkers/blood/metabolism MH - Case-Control Studies MH - Chemokine CCL2/blood/metabolism MH - Female MH - Humans MH - Inflammation/*blood/metabolism MH - Intercellular Adhesion Molecule-1/blood/metabolism MH - Interleukin-6/blood/metabolism MH - Male MH - Matrix Metalloproteinase 8/*blood/metabolism MH - Matrix Metalloproteinase 9/*blood/metabolism MH - Metabolic Syndrome/*blood/metabolism MH - Middle Aged MH - Selectins/blood/metabolism MH - Tissue Inhibitor of Metalloproteinase-1/blood/metabolism MH - Tissue Inhibitor of Metalloproteinase-2/blood/metabolism EDAT- 2009/03/04 09:00 MHDA- 2009/07/07 09:00 CRDT- 2009/03/04 09:00 PHST- 2008/11/28 00:00 [received] PHST- 2009/02/19 00:00 [revised] PHST- 2009/02/20 00:00 [accepted] PHST- 2009/03/04 09:00 [entrez] PHST- 2009/03/04 09:00 [pubmed] PHST- 2009/07/07 09:00 [medline] AID - S0009-8981(09)00110-7 [pii] AID - 10.1016/j.cca.2009.02.013 [doi] PST - ppublish SO - Clin Chim Acta. 2009 May;403(1-2):173-7. doi: 10.1016/j.cca.2009.02.013. Epub 2009 Feb 28.